anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clinical event detection and recording using active learning are disclosed. The claimed techniques include maintaining sequences of sentences. Each sequence of sequences is associated with an entity, and each sentence in each sequence is associated with a label and a timestamp. The techniques include iteratively training a machine-learning model using each sentence of the sequences as input and the label as a ground-truth value. Each iteration of training includes generating a prediction indicating whether the timestamp of each sentence occurred before or after an event of the entity. Each iteration of training includes validating the machine-learning model based on the prediction and the label of each sentence and the ground-truth value.
The ULTRA-STEMI trial is a prospective investigator-initiated single-centre single-arm observational cohort study aiming to enroll 80 consecutive patients presenting with ST-segment elevation myocardial infarction (STEMI) and undergoing IVUS-guided primary PCI. IVUS will be performed at baseline, post-intervention and post-optimization. Baseline tissue characterization includes the morphological description of culprit lesion plaque and thrombus characteristics as assessed with IVUS. In patients with large thrombus burden, manual thrombus aspiration will be performed according to clinical indications. The aspirated thrombi will be collected and scanned with micro-computed tomography (micro-CT) to correlate IVUS measurements with micro-CT thrombus quantification. Also, angiographic data will be gathered to correlate IVUS measurements with pre-and post-PCI angiographic information. Post-PCI instantaneous wave-free ratio (IFR) will also be performed to assess the severity of the residual coronary-artery stenosis, if any. All patients will be followed up for at least 12 months for the adjudication of major adverse cardiovascular events.The primary endpoint will be target vessel failure at 12 months (defined as a composite of cardiac death, target vessel myocardial infarction and clinically driven target vessel revascularization). The secondary outcomes of interest will be: radiation exposure, contrast use and kidney function effects. Other endpoints include clinical and angiographic outcomes along with post-PCI IVUS, iFR and micro-CT findings.
In this quasi-experimental pilot study, a Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) will be introduced by a specifically dedicated team with physicians trained in this practice. In order to allow a chance for return of spontaneous circulation (ROSC) with standard care, REBOA will be placed after 10 minutes of conventional CPR. Conventional CPR will be performed using innovative devices to enhance circulation and cerebral perfusion pressure during CPR, including progressive elevation of the head and thorax, an active chest compression device, and an impedance threshold valve.
To provide antibody-based cancer therapeutics that retain cytotoxic effect for targeted drug delivery to provide reliable and improved anti-tumor efficacy over prior therapeutics.SOLUTION: Provided are optionally lyophilized nanoparticles comprising a carrier protein, an antibody, and a therapeutic agent. The nanoparticles provide targeted therapy to a tumor while minimizing toxicity to the patient. In one aspect, provided are nanoparticle compositions comprising nanoparticles. Each of the nanoparticles comprises a carrier protein, between about 100 to about 1000 antibodies, and optionally at least one therapeutic agent. The antibodies are arranged outward from the surface of the nanoparticles. The nanoparticles are capable of binding to a predetermined epitope in vivo.SELECTED DRAWING: Figure 1B
A herbal healing lotion in the form of a topical composition for relieving dermatological skin conditions encountered by animals. The composition is topically applied to an affected area of skin of the animal. The topical composition contains a vehicle for distributing the active ingredients to the affected skin. The vehicle is comprised of water, carboxymethylcellulose, and colostrum which allows for the active ingredients to be received by the skin on surface and deep tissue layers. The herbal healing lotion contains no steroid or antibiotic component thereby preventing immunosuppression generally associated therewith. The herbal healing lotion combines natural ingredients in a topical composition to successfully treat dermatological conditions previously held as untreatable.
The main intervention of this study is a \[18F\]PD-L1 PET scan. In both phase one and phase two a scan sequence will be performed both at baseline and 6 weeks after initiation of nivolumab treatment. The PET scans will be combined with either a low dose or diagnostic CT scan of chest, abdomen and pelvis and a MRI of the brain. In phase two, a biopsy of at least one accessible lesion will be performed to analyze PD-L1 expression using immunohistochemical staining after each PET scan.
Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (\>350 volunteers to date).
A system and method for monitoring patient adherence to prescribed medications include a processor that analyzes prior authorization data and insurance claims data based on adherence rules, which are user configurable. The system assigns non-adherence cases for user review by creating work queues. Queues may be associated with respective user roles. In response to a non-adherence case, the system generates automated notifications using a notification template. Placeholder variables are insertable into the templates to describe a parameter applicable to a specific instance of non-adherence. The placeholder is replaced by an actual value of the parameter when a notification document is subsequently generated.
The invention relates to a compound risperidone subcutaneous embedded sustained-release preparation and a preparation method thereof. The sustained-release preparation is prepared from the following raw materials in parts by weight: 100 parts of risperidone and 0.00247 part of propionic acid sustained-release preparation. The preparation method comprises the following step of uniformly mixing risperidone and the propionic acid sustained-release preparation into granules which are wrapped in a plurality of medical silicon rubber tubes. The compound risperidone subcutaneous embedded sustained-release preparation provided by the invention can be guided and embedded in a loose part of the subcutaneous tissue of the inferior abdominal wall of a patient by means of a small incision with a sleeve needle after getting a satisfactory effect of acute treatment of the patient, and 8-10 subcutaneous embedded sustained-release preparations can be embedded at one time. The subcutaneous embedded sustained-release preparation is lasting in curative effect and economical and practical, and the one-time embedding curative effect is controlled within about 1 year. Medicines guided by the sustained-release preparation are slowly and uniformly released through a medical silica gel thin film wall to ensure stable and effective blood concentration so as to realize the purpose of maintaining treatment. The subcutaneous embedded sustained-release preparation provided by the invention is suitable for patients with various schizophrenia, mood disorders, multiple Tourette syndrome and other risperidone treatment indications.
Atazanavir has been shown to increase tenofovir concentrations [See Clinical Pharmacology (12.3)]. The mechanism of this interaction is unknown. Patients receiving atazanavir and TRUVADA should be monitored for TRUVADA-associated adverse reactions. TRUVADA should be discontinued in patients who develop TRUVADA-associated adverse reactions.

Tenofovir decreases the AUC and Cmin of atazanavir [See Clinical Pharmacology (12.3)]. When coadministered with TRUVADA, it is recommended that atazanavir 300 mg is given with ritonavir 100 mg. Atazanavir without ritonavir should not be coadministered with TRUVADA.
Nursing home (NH) residents with dementia are often dependent on others for mouth care, yet will react with care-resistant behavior (CRB) when receiving assistance. The oral health of these elders deteriorates in the absence of daily oral hygiene, predisposing them to harmful systemic problems such as pneumonia, hyperglycemia, cardiac disease, and cerebral vascular accidents. The purpose of this study is to determine whether CRBs can be reduced, and oral health improved, through the application of an intervention based on the neurobiological principles of threat perception and fear response. When faced with a threat, all organisms react with "flight-fight" responses. These responses are both autonomic (e.g. elevated heart rate, sweating) and behavioral (e.g. moving away, attacking). Persons with dementia have heightened threat perception as a result of neurobiological changes that affect the cerebral cortex, hippocampus, and amygdala. These individuals may interpret mouth care as a threatening action by threatening people. The intervention, called Managing Oral Hygiene Using Threat Reduction (MOUTh), combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate CRB. The primary specific aims of the study are to: 1)Evaluate the efficacy of the MOUTh intervention for reducing CRBs in persons with dementia; 2)Validate the overall efficacy of the MOUTh intervention using nurse-sensitive oral health outcomes--swollen and bleeding gums, cleanliness of the oral cavity, saliva, and integrity of the lips and oral mucosa; and 3)Calculate the cost of the MOUTh intervention. Using a randomized repeated measures design, 80 elders with dementia from 5 different NHs will be randomized at the individual level to the experimental group, which will receive the intervention, or to the control group, which will receive standard mouth care from research team members who receive training in the proper methods for providing mouth care but no training in resistance recognition or prevention/mediation. Oral health assessments and CRB measurements will be obtained during a 7-day observation period and a 21-day intervention period. Individual growth models using multilevel analysis will be used to estimate the efficacy of the intervention for reducing CRBs in persons with dementia, and to estimate the overall efficacy of the intervention using oral health outcomes. Activity-based costing methods will be used to determine the cost of the MOUTh intervention. At the end of this study, the research team anticipates having a proven intervention that prevents and reduces CRB within the context of mouth care. Long-term objectives include testing the effect of the intervention on systemic illnesses among persons with dementia; examining the transferability of this intervention to other activities of daily living; and disseminating threat reduction interventions to NH staff, which may radically change the way care is provided to persons with dementia.
PURPOSE:To quickly perform permanent wave treatment giving little damage to the human body, scalp and hair while shortening the hair-fixing time by reducing and softening hair and oxidizing and fixing the softened hair with an aqueous solution containing transition metal ion. CONSTITUTION:Hair is reduced and softened with a 1st solution containing an organic acid having thiol group and the softened hair is fixed with a 2nd solution containing an oxidizing agent (e.g. bromic acid salt). The hair is treated with an aqueous solution containing a transition metal ion after the treatment with the 1st solution and before the oxidative fixing treatment or during the oxidative fixing stage to effect the permanent wave treatment of the hair. The oxidative fixing is preferably carried out in an oxygen-enriched air atmosphere and the transition metal ion is e.g. Fe ion and Cu ion.
Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current (if head circumference \>52cm; children with head circumference 43-52cm will receive 1-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments.
The invention relates to a method for treating skin blackhead. According to the method, 8-10% of edible sodium bicarbonate, 3-5% of honey, 3-5% of egg white and water having a temperature of 20-30 DEG C are stirred to form paste. The method concretely comprises the following steps of putting edible sodium bicarbonate into a container, fully dissolving the edible sodium bicarbonate by water having a temperature of 20-30 DEG C and a use amount 5 times that of the edible sodium bicarbonate, adding honey and egg white into the solution, carrying out stirring to obtain uniform paste for next use, cleaning face, covering a hot towel on the face for 1min so that skin pores are opened, and smearing skin blackhead with the paste by a cotton swab, and carrying out cleaning to remove the paste after 10-15min, wherein the smearing process is carried out once every day. Through combination of the above three materials, the method can fast remove skin blackhead. Through the method, the skin blackhead can be removed in 2-3 days, a cure rate is 100%, and scar and relapse are avoided. The method has simple preparation processes.
The present invention discloses an oral compound preparation for treating dermatosis, which is No. 1 to 5 formula medicine prepared through pulverization, mixing and particle / tablet preparation. Each particle / tablet at least contains the raw materials with the following weight compounding ratio: 1 to 2 mg of chlorpheniramine maleate, 0.2 to 0.8 mg of dexamethasone, vitamins A3 to 5u, vitamins D3 to 5u, 20 to 30 mg of vitamin B1, 1 to 3 mg of vitamin B2, 40 to 60 mg of vitamin C, 1 to 2 mg of nicotinamide and 200 to 300 mg of calcium monophosphate. Aiming at different dermatosis, promethazine, sulfanilamide, nystatin, griseofulvin, cimetidine, virazole, erythromycin or tetracycline, etc. can be added. The oral compound preparation has the advantages of strong pertinence, wide entity treatment, short treating course, obvious effect, high cure rate, economy, low cost, wide application groups and no obvious toxic or side effect, and external medicine does not need to be used when the oral compound preparation is taken. The radical cure purposes of taking a temporary solution and effecting permanent cure are certainly achieved.
Patients receive botensilimab IV over 30 minutes on day 1 of each cycle for up to 4 cycles. Patients receive balstilimab IV over 30 minutes and vitamin C IV over 30 minutes on days 1, 15 and 29 of each cycle. Patients undergo a FMD on days -4 to -1 of each cycle. Cycles repeat every 42 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, CT scans and MRI throughout the study.
Methods for training an algorithm to identify structural anatomical features, for example of a blood vessel, in a non-contrast computed tomography (NCT) image are described herein. The algorithm may comprise an image segmentation algorithm, a random forest classifier, or a generative adversarial network in examples described herein. In one embodiment, a method comprises receiving a labelled training set for a machine learning image segmentation algorithm. The labelled training set comprising a plurality of NCT images, each NCT image of the plurality of NCT images showing a targeted region of a subject, the targeted region including at least one blood vessel. The labelled training set further comprises a corresponding plurality of segmentation masks, each segmentation mask labelling at least one structural feature of a blood vessel in a corresponding NCT image of the plurality of NCT images. The method further comprises training a machine learning image segmentation algorithm, using the plurality of NCT images and the corresponding plurality of segmentation masks, to learn features of the NCT images that correspond to structural features of the blood vessels labelled in the segmentation masks, and output a trained image segmentation model. The method further comprises outputting the trained image segmentation model usable for identifying structural features of a blood vessel in an NCT image. Further methods are described herein for identifying anatomical features from an NCT image, and for establishing training sets. Computing apparatuses and computer readable media are also described herein.
BACKGROUND: Information and communication technologies (ICTs) have been positioned as useful tools to facilitate self-care. The interaction between a patient and technology, known as usability, is particularly important for achieving positive health outcomes. Specific characteristics of patients with chronic diseases, including multimorbidity, can affect their interaction with different technologies. Thus, studying the usability of ICTs in the field of multimorbidity has become a key element to ensure their relevant role in promoting self-care.
OBJECTIVE: The aim of this study was to analyze the usability of a technological tool dedicated to health and self-care in patients with multimorbidity in primary care.
METHODS: A descriptive observational cross-sectional usability study was performed framed in the clinical trial in the primary care health centers of Madrid Health Service of the TeNDER (Affective Based Integrated Care for Better Quality of Life) project. The TeNDER technological tool integrates sensors for monitoring physical and sleep activity along with a mobile app for consulting the data collected and working with self-management tools. This project included patients over 60 years of age who had one or more chronic diseases, at least one of which was mild-moderate cognitive impairment, Parkinson disease, or cardiovascular disease. From the 250 patients included in the project, 38 agreed to participate in the usability study. The usability variables investigated were effectiveness, which was determined by the degree of completion and the total number of errors per task; efficiency, evaluated as the average time to perform each task; and satisfaction, quantified by the System Usability Scale. Five tasks were evaluated based on real case scenarios. Usability variables were analyzed according to the sociodemographic and clinical characteristics of patients. A logistic regression model was constructed to estimate the factors associated with the type of support provided for task completion.
RESULTS: The median age of the 38 participants was 75 (IQR 72.0-79.0) years. There was a slight majority of women (20/38, 52.6%) and the participants had a median of 8 (IQR 7.0-11.0) chronic diseases. Thirty patients completed the usability study, with a usability effectiveness result of 89.3% (134/150 tasks completed). Among the 30 patients, 66.7% (n=20) completed all tasks and 56.7% (17/30) required personalized help on at least one task. In the multivariate analysis, educational level emerged as a facilitating factor for independent task completion (odds ratio 1.79, 95% CI 0.47-6.83). The median time to complete the total tasks was 296 seconds (IQR 210.0-397.0) and the median satisfaction score was 55 (IQR 45.0-62.5) out of 100.
CONCLUSIONS: Although usability effectiveness was high, the poor efficiency and usability satisfaction scores suggest that there are other factors that may interfere with the results. Multimorbidity was not confirmed to be a key factor affecting the usability of the technological tool.
TRIAL REGISTRATION: Clinicaltrials.gov NCT05681065; https://clinicaltrials.gov/study/NCT05681065.
Recent studies suggest sugar-sweetened beverage (SSB) consumption has been declining among US children 2-18y. However, most studies focus on changes in mean intake and little is known about trends in the high SSB consumers who are most at risk of excess weight gain. There is also limited understanding of whether and how these changes over time may have influenced disparities in intake among vulnerable groups of children with persistently high levels of obesity, including children from low-income households, and several race-/ethnic minorities.

This analysis of six cycles of US National Health and Nutrition Examination Survey (NHANES) dietary surveillance data from 2003-2014 examined shifts over time in SSB intake at both the median and 90th percentile among US children. The study evaluated the extent to which disparities in intake of total SSBs, as well as major SSB subtypes (regular sodas, fruit drinks and other), may have persisted in vulnerable groups, for both median and "heavy" intake. The analysis presents data for three age groups: 2-5y, 6-11y and 12-18y by gender, and focus on three race-ethnic groups: Non-Hispanic White, Non-Hispanic Black, and Mexican-American. Household income is used as the primary socioeconomic status variable.
Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
Women in early labor frequently request pain medication. Obstetricians may prescribe narcotics (administered as an intravenous (IV) or intramuscular (IM) injection). However, IV or IM narcotics provide incomplete pain relief and have maternal and fetal/neonatal side effects, e.g., maternal drowsiness, respiratory depression, nausea, vomiting, and neonatal respiratory depression. Other obstetricians allow their patients to request early neuraxial (spinal or epidural) analgesia. The results of several studies comparing patients who received epidural versus IV/IM narcotic labor analgesia (not specifically in early labor)suggest that initiation of early neuraxial analgesia may be associated with higher Cesarean delivery rates. It has been hypothesized that epidural/spinal local anesthetics may induce pelvic musculature relaxation leading to failure of fetal descent and rotation. However, early pain may be a marker for other factors that increase the risk of Cesarean delivery, e.g., large or malpositioned baby, or dysfunctional labor. Whether or not early neuraxial analgesia (particularly if narcotic based, which would not cause pelvic muscle paralysis) compared to IV/IM narcotics, adversely affects the outcome of labor has not been studied in a randomized, prospective fashion. The purpose of this study is to compare Cesarean and forcep delivery rates, and quality of pain relief, in first-time mothers undergoing induction of labor who receive neuraxial versus IV/IM analgesia for early labor (cervical dilation \< 4 cm).